InvestorQ : What is your view on Biocon’s latest pact with Voluntis?
Rashi Mehra made post

What is your view on Biocon’s latest pact with Voluntis?

Answer
user profile image
sarah Leo answered.
3 months ago


Biocon Biologics, a unit of Biocon Ltd, has entered into an agreement with Voluntis for digital therapeutics for insulin. This insulia digital companion will be offered to people suffering from Type-2 diabetes. Insulia globally offers automated insulin dose recommendations enabling people with diabetes to self-manage their condition.

Interestingly, this is a new concept and Insulia is the first digital therapeutic solution with regulatory approval. Biocon Biologicals expects that pairing its product with a digital therapeutic solution will improve patient outcomes and also substantially reduce the cost of healthcare for patients. The US is one of the biggest markets for this solution.